Global Centre of Edible Cannabis Product
Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to announce it has established the first dedicated Research and Development Center (the “Centre”) in the area of medical and nutritional edible cannabis in its Mernova Medicinal Site in Nova Scotia, Canada.
pixabay/7raysmarketing
The Centre will focus on unique, edible formulations utilizing precision engineered cannabis extracts and non cannabis ingredients that, when combined, deliver an enhanced experience. This Centre will further establish Creso as the leader in producing trusted, pharma-grade, edible cannabis products.
Creso has relationships with academic institutions in each country where it has operations (Canada, Switzerland, Colombia and Israel) and will leverage this for additional support in research, analytical insights and product innovation.
“For the first time we see a company bringing together international knowledge in the field of medicinal and nutritional cannabis. It’s a fascinating initiative” said Prof. Dr. Felix Gutzwiller, former Director of the Institute for Prevention and Public Health at the University of Zürich.
“This is a great example of consolidated international academic research work being applied directly in practice.”
“Creso has the substantial competitive advantage of being operationally present in those countries which have the scientific and operational lead in medicinal cannabis namely Canada, Israel and Colombia,” said Boaz Wachtel, Chairman of Creso.
“This will lead to substantial patient benefits and improved health outcomes through more accurate therapeutic approaches with medicinal cannabis.”
Creso’s COO John Griese said: “Following successful launches of cannaQIX®10 and cannaQIX® 50 it is clear demand for safe, effective, edible products is growing at a tremendous rate. It is not only a good business decision but it’s our responsibility in this emerging industry to apply rigour to cannabis product design. The Centre will assume this responsibility on behalf of Creso.”
Creso’s Co-founder and CEO Dr. Miri Halperin Wernli, said: “In our development and research centre we will create high-quality, purposefully designed and lab-tested products which will cater for specific applications such as sleep, pain or anxiety. The products will be enriched with appealing terpene profiles enhancing their health and wellness benefits.
“Like with fine wine and craft beer, premium cannabis consumers want enhanced experiences that fit their lifestyle and from premium products of the highest quality. Creso is dedicated to taking an active role in setting the standards for the cannabis industry and performing beyond expectations to make safe, reliable products. The Centre of Edible Cannabis Product Development and Research is one big step toward that vision.”
Creso is also in advanced talks with the National University of Colombia in Bogota and University of Antioquia (UdeA), Medellin for local operational and research and development activities.
Substantial funds have been allocated to the installation of the GMP lab, test kitchen and processing capability. Building construction is complete and the facility is expected to be operational by end Q1 2019.
Other news from the department science
Get the food & beverage industry in your inbox
From now on, don't miss a thing: Our newsletter for the food & beverage sector brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
